4SC Says Anti-Cancer Compound Resminostat Gets Positive Opinion

4SC AG (VSC) said its anti-cancer compound Resminostat was designated by the European Medicines Agency as orphan medicinal product for the treatment of Hodgkin’s Lymphoma.

To contact the editor responsible for this story: Mariajose Vera at mvera1@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.